AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03583021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine Injectable Product
Description: Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
Study NCT03303729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat Hydrolysate
Description: 25 grams of meat hydrolysate to maximally stimulate protein synthesis.
Study NCT04565522 — intervention group
Intervention type: OTHER
Intervention: Prospective observation
Description: Prospective observation until one year follow-up
Study NCT03303729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meat Hydrolysate
Description: 25 grams of meat hydrolysate to maximally stimulate protein synthesis.
Study NCT02242929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream with prior curettage
Study NCT02242929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical excision
Study NCT00695006 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Traction
Description: Traction \<5lbs
Study NCT00695006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traction
Description: Standard supine intermittent traction
Study NCT00739102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.M.A.R.T. ® Stent
Description: The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
Study NCT02457702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orally administered labeled glycerol
Description: Oral administration of labeled glycerol
Study NCT00868595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-101
Description: Vaccine
Study NCT00868595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: Activating agent, infusion
Study NCT04095286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference AMB (5 mg)
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
Study NCT05234814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.
Description: Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006).
Study NCT05234814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine auricular acupuncture point buried seeds therapy
Description: Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006).
Study NCT03535701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo ketogenic diet
Study NCT03535701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03535701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03535701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given standard of care therapy with paclitaxel
Study NCT03535701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given standard of care therapy with paclitaxel
Study NCT03535701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03535701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03535701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03535701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04498533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: forearm strap (counterforce brace)
Study NCT03303729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cluster Dextrin
Description: 75 grams of Cluster Dextrin
Study NCT03303729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 75 grams of Glucose
Study NCT00810602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduced intensity, related donor stem cell transplant
Description: Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant.
Study NCT00810602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (standard GVHD prophylaxis)
Description: Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
Study NCT00810602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate (standard GVHD prophylaxis)
Description: Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
Study NCT00810602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study.
Study NCT01396421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712 [Brexpiprazole] High Dose
Description: Higher dose, tablet, once daily, for six weeks
Study NCT01396421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: OPC-34712 [Brexpiprazole] Middle Dose
Description: Middle dose, tablet, once daily, for six weeks
Study NCT01396421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: OPC-34712 [Brexpiprazole] Low Dose
Description: Lower dose, tablet, once daily, for six weeks
Study NCT01396421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, for six weeks
Study NCT00392782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
Study NCT00392782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).
Study NCT00392782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
Study NCT00392782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
Study NCT00392782 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
Study NCT02561234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV
Study NCT03259685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 710 ml of regular soft drinks, taken daily for 10 weeks
Description: Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
Study NCT03259685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 710 ml of diet soft drinks, taken daily for 10 weeks
Description: Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
Study NCT03259685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks
Description: Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
Study NCT03146273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Description: After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins.
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tildrakizumab
Description: Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
Study NCT03997786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Weeks 0 to 16)
Study NCT03974854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOXIRI-3
Description: chemotherapy with XELOXIRI-3 regimen
Study NCT03974854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: chemotherapy with Gemcitabine regimen
Study NCT01286233 — intervention group
Intervention type: DRUG
Intervention: Metformin
Study NCT01286233 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT02118883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Essentia Water
Study NCT02118883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bottled water
Study NCT04465110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
Study NCT04465110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape Seed Extract
Description: Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
Study NCT02272426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARET
Description: Combined Aerobic and Resistance Exercise Training
Study NCT02272426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTI
Description: Cognitive Training Intervention
Study NCT02272426 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham CARET
Description: Sham Combined Aerobic and Resistance Exercise Training
Study NCT02272426 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham CTI
Description: Sham Cognitive Training Intervention
Study NCT01522248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza vaccine
Description: 0.5 ml IM once only
Study NCT03719586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZMapp
Description: Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
Study NCT03719586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight >= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight >= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
Study NCT03719586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAb114
Description: 50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Study NCT03719586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN-EB3
Description: 150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Study NCT03713892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-504
Description: orally administered once with investigational drug assigned on 1d morning with 240 mL of water
Study NCT03713892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered
Study NCT01360593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles.
Study NCT01360593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles.
Study NCT01360593 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day.
Study NCT02639767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
Study NCT02639767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pleural Intensity Modulated Radiation Therapy
Description: Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
Study NCT03254914 — intervention group
Intervention type: PROCEDURE
Intervention: Home Blood Pressure
Description: Measure Home Blood Pressure
Study NCT03224845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural skills training
Description: The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
Study NCT04498533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape application
Study NCT01402284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
Study NCT01402284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
Study NCT01402284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
Study NCT01402284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
Study NCT01402284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
Study NCT03816306 — intervention group
Intervention type: DRUG
Intervention: LCZ 696
Description: LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
Study NCT02290535 — intervention group
Intervention type: PROCEDURE
Intervention: patients
Description: The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
Study NCT02639767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
Study NCT03566784 — intervention group
Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: Standard procedure for inguinal hernia repair
Study NCT02191137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
Study NCT04560036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FAZA PET/MRI scan
Description: FAZA PET/MRI scan before and after the standard of care chemotherapy